<?xml version='1.0' encoding='utf-8'?>
<document id="23436490"><sentence text="Competitive binding of fluoroquinolone antibiotics and some other drugs to human serum albumin: a luminescence spectroscopic study."><entity charOffset="23-38" id="DDI-PubMed.23436490.s1.e0" text="fluoroquinolone" /></sentence><sentence text="Co-administration of several drugs in multidrug therapy may alter the binding of each to human serum albumin (HSA) and hence their pharmacological activity" /><sentence text=" Thirty-two frequently prescribed drug combinations, consisting of four fluoroquinolone antibiotics and eight competing drugs, have been studied using fluorescence and circular dichroism spectroscopic techniques"><entity charOffset="72-87" id="DDI-PubMed.23436490.s3.e0" text="fluoroquinolone" /></sentence><sentence text=" Competitive binding studies on the drug combinations are not available in the literature" /><sentence text=" In most cases, the presence of competing drug decreased the binding affinity of fluoroquinolone, resulting in an increase in the concentration of free pharmacologically active drug"><entity charOffset="81-96" id="DDI-PubMed.23436490.s5.e0" text="fluoroquinolone" /></sentence><sentence text=" The competitive binding mechanism involved could be interpreted in terms of the site specificity of the binding and competing drugs" /><sentence text=" For levofloxacin, the change in the binding affinity was small because in the presence of site II-specific competing drugs, levofloxacin mainly occupied site I"><entity charOffset="5-17" id="DDI-PubMed.23436490.s7.e0" text="levofloxacin" /><entity charOffset="125-137" id="DDI-PubMed.23436490.s7.e1" text="levofloxacin" /><pair ddi="false" e1="DDI-PubMed.23436490.s7.e0" e2="DDI-PubMed.23436490.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23436490.s7.e0" e2="DDI-PubMed.23436490.s7.e1" /></sentence><sentence text=" A competitive interference mechanism was operative for sparfloxacin, whereas competitive interference as well as site-to-site displacement of competing drugs was observed in the case of ciprofloxacin hydrochloride"><entity charOffset="56-68" id="DDI-PubMed.23436490.s8.e0" text="sparfloxacin" /><entity charOffset="187-214" id="DDI-PubMed.23436490.s8.e1" text="ciprofloxacin hydrochloride" /><pair ddi="false" e1="DDI-PubMed.23436490.s8.e0" e2="DDI-PubMed.23436490.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23436490.s8.e0" e2="DDI-PubMed.23436490.s8.e1" /></sentence><sentence text=" For enrofloxacin, a different behavior was observed for different combinations; site-to-site displacement and conformational changes as well as independent binding has been observed for various drug combinations"><entity charOffset="5-17" id="DDI-PubMed.23436490.s9.e0" text="enrofloxacin" /></sentence><sentence text=" Circular dichroism spectral studies showed that competitive binding did not cause any major structural changes in the HSA molecule" /><sentence text="" /></document>